Prolonged efficacy of infliximab for refractory adult-onset Still's disease.
Dilhuydy
M S
MS
Vatan
R
R
Etienne
G
G
Longy-Boursier
M
M
Mercié
P
P
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D000069285:Infliximab; D016706:Still's Disease, Adult-Onset / Q000188:drug therapy*; D013997:Time Factors; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab